| 摘要: |
| 目的 探讨四氢姜黄素对S180荷瘤小鼠肿瘤生长的抑制作用,并初步探究不同制剂技术的非临床安全性特征。方法 裸鼠分为正常对照组(Control)、荷瘤模型组(Model)、 环磷酰胺组(CTX)、 四氢姜黄素组(THC),构建S180荷瘤模型后,THC组给予200 mg·kg-1的四氢姜黄素悬浊液,CTX组给予20 mg·kg-1的环磷酰胺,正常对照组和荷瘤组给予等体积5% CMC-Na,连续15 d,比较各组肿瘤生长、免疫应答及氧化应激水平;采用普通混悬液或固体分散体制剂制成制剂,在大鼠中开展初步的非临床安全性探究,比较不同制剂的一般毒理学特征。结果 THC组肿瘤体积、瘤重低于荷瘤模型组(P<0.05),小鼠胸腺和脾指数明显升高,白细胞介素-2(IL-2)、肿瘤坏死因子α(TNF-α)及干扰素-γ(IFN-γ)均高于荷瘤模型组(P<0.05),动物CD4+T细胞比例明显升高、CD8+T细胞比率均降低(P<0.01),提示THC可明显的促进T细胞向肿瘤微环境的浸润及活化;THC组血清超氧化歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)水平高于其他组,丙二醛(MDA)、乳酸脱氢酶(LDH)水平低于模型组(P<0.05)。THC肿瘤组织Nrf2和HO-1蛋白表达水平低于荷瘤模型组(P<0.01)。大鼠重复4 周给药毒性探索性试验中可见固体分散体技术制剂具有更高的安全性特征。结论 四氢姜黄素具有剂量依赖性的抑制肿瘤生长作用,其抗肿瘤作用机制可能与增强荷瘤小鼠机体组织抗氧化能力,促进T细胞向肿瘤微环境的浸润及活化。与常规混悬制剂相比,四氢姜黄素采用固体分散体技术开发的制剂具有更高的安全性特征。 |
| 关键词: 四氢姜黄素 抗肿瘤 免疫应答 抗氧化 氧化应激 非临床安全性 固体分散体技术 |
| DOI:10.13506/j.cnki.jpr.2025.12.006 |
| 基金项目: |
|
Publication Date:December 25, 2025
|
|
| Mechanism of tumor inhibition of tetrahydrocurcumin on S180 tumor bearing mice and non clinical safety study of different formulations |
| ZANG Bo1,WANG Li1,ZANG Junyi2,ZHAN Lingqing3 |
| (1.Qingdao Eighth People's Hospital,Qingdao 266121,China;2.Shandong University of Traditional Chinese Medicine,Jinan 250355,China;3.Jinjialing Street Community Health Service Center,Laoshan District,Qingdao 266035,China) |
| Abstract: |
| Objective To investigate the effects of trahydrocurcumin on immune function and antioxidant capacity in S180 tumor bearing mice. At the same time, preliminary exploration of the non-clinical safety characteristics of different formulation technologies.Methods The nude mice were divided into a normal control group (Control), a tumor bearing model group (Model), a cyclophosphamide group (CTX), and a tetrahydrocurcumin group (THC). After constructing the S180 tumor bearing model, the THC group was given 200 mg·kg-1 tetrahydrocurcumin suspension, the CTX group was given 20 mg·kg-1 cyclophosphamide, and the normal control group and tumor bearing group were given equal volumes of 5% CMC Na for 15 consecutive days. The tumor growth, immune response, and oxidative stress levels of each group were compared; Formulations were prepared using ordinary suspensions or solid dispersions, and preliminary non clinical safety studies were conducted in rats to compare the general toxicological characteristics of different formulations.Results The tumor volume and weight of the THC group were significantly lower than those of the tumor bearing model group (P<0.05). The thymus and spleen indices of mice were significantly increased, and IL-2, TNF-α, and IFN-γ were significantly higher than those of the tumor bearing model group (P<0.05). The proportion of CD4+T cells in animals was significantly increased, and the proportion of CD8+T cells was significantly decreased (P<0.01), indicating that THC can significantly promote the infiltration and activation of T cells into the tumor microenvironment; The levels of serum SOD and GSH Px in the THC group were higher than those in the other groups, while the levels of MDA and LDH were significantly lower than those in the model group (P<0.05). The expression levels of Nrf2 and HO-1 proteins in THC tumor tissue were significantly lower than those in the tumor bearing model group (P<0.01). In the exploratory toxicity test of repeated 4-week administration in rats, it was observed that solid dispersion technology formulations have higher safety characteristics.Conclusion Tetrahydro curcumin has a dose-dependent inhibitory effect on tumor growth, and its anti-tumor mechanism may be related to enhancing the antioxidant capacity of tumor bearing mouse tissues, promoting T cell infiltration and activation into the tumor microenvironment. Compared with conventional suspension formulations, the formulation of tetrahydrocurcumin developed using solid dispersion technology has higher safety characteristics. |
| Key words: Trahydrocurcumin Anti-tumor Immune response Antioxidation Oxidative stress Non-clinical safety Repeated dose toxicity Solid dispersion technology |